# A Real-life Study to Learn About the Use and Effects of the CDK4/6 Inhibitors in Canadian Patients With Breast Cancer.

> **NCT05770713** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 48 (actual)

## Conditions studied

- Breast Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05770713
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-12
- **Primary completion:** 2023-02-28
- **Final completion:** 2023-02-28
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2024-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05770713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05770713, "A Real-life Study to Learn About the Use and Effects of the CDK4/6 Inhibitors in Canadian Patients With Breast Cancer.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05770713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*